Dear GRG Member,
An advance toward aging interventions.
Scientists successfully edit human immune-system T cells
- The CRISPR/Cas9 system makes it possible to easily and inexpensively edit genetic information in virtually any organism.
- T cells, which circulate in the blood, are an obvious candidate for medical applications of the technology, as these cells not only stand at the center of many disease processes, but could be easily gathered from patients, edited with CRISPR/Cas9, then returned to the body to exert therapeutic effects.
- A protein on the T-cell surface called CXCR4 was disabled. CXCR4 can be exploited by HIV.
- The group successfully shut down PD-1, a protein that has attracted intense interest in the burgeoning field of cancer immunotherapy, as scientists have shown that using drugs to block PD-1 coaxes T cells to attack tumors.
- Alexander Marson, PhD, a UCSF Sandler Fellow says it’s difficult, and the group is driving as hard as they can toward applications.
- The new work was done under the auspices of the Innovative Genomics Initiative (IGI), a joint UC Berkeley-UCSF program co-directed by Berkeley’s Jennifer Doudna, PhD, and Jonathan Weissman PhD.
- More details about the program, IGI, supporters and UCSF follow.
I heard about this first from Kurzweil AI